Skip to main content

Advertisement

SpringerLink
Log in

DIABETIC KIDNEY DISEASE

Organ protection beyond glycaemic control with SGLT2 inhibitors

  • News & Views
  • Published:

From Nature Reviews Nephrology

View current issue Sign up to alerts

Recent clinical trials demonstrated that sodium–glucose co-transporter 2 inhibitors can reduce hospitalization for heart failure and improve hard kidney end points in patients with and without type 2 diabetes mellitus. These observations consolidate the view that organ protection is independent of blood glucose control and mitigation of traditional risk factors.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1: Clinical trials expand the populations that benefit from SGLT2 inhibition.

References

  1. Zinman, B. et al. Empagliflozin, Cardiovascular outcomes, and mortality in type 2 diabetes. N. Engl. J. Med. 373, 2117–2128 (2015).

    Article  CAS  Google Scholar 

  2. Neal, B. et al. Canagliflozin and cardiovascular and renal events in type 2 diabetes. N. Engl. J. Med. 377, 644–657 (2017).

    Article  CAS  Google Scholar 

  3. Wiviott, S. D. et al. Dapagliflozin and cardiovascular outcomes in type 2 diabetes. N. Engl. J. Med. 380, 347–357 (2019).

    Article  CAS  Google Scholar 

  4. Perkovic, V. et al. Canagliflozin and renal outcomes in patients with type 2 diabetes and nephropathy. N. Engl. J. Med. 380, 2295–2306 (2019).

    Article  CAS  Google Scholar 

  5. McMurray, J. J. V. et al. Dapagliflozin in patients with heart failure and reduced ejection fraction. N. Engl. J. Med. 381, 1995–2008 (2019).

    Article  CAS  Google Scholar 

  6. Packer, M. et al. Cardiovascular and renal outcomes with empagliflozin in heart failure. N. Engl. J. Med. 383, 1413–1424 (2020).

    Article  CAS  Google Scholar 

  7. Heerspink, H. J. L. Dapagliflozin in patients with chronic kidney disease. N. Engl. J. Med. 383, 1436–1446 (2020).

    Article  CAS  Google Scholar 

  8. Zannad, F. et al. SGLT2 inhibitors in patients with heart failure with reduced ejection fraction: a meta-analysis of the EMPEROR-Reduced and DAPA-HF trials. Lancet 396, 819–829 (2020).

    Article  Google Scholar 

  9. Pardeep S Circulation. Efficacy of dapagliflozin on renal function and outcomes in patients with heart failure with reduced ejection fraction: results of DAPA-HF https://doi.org/10.1161/CIRCULATIONAHA.120.050391 (2020).

  10. Anker, S. D. et al. Evaluation of the effects of sodium-glucose co-transporter 2 inhibition with empagliflozin on morbidity and mortality in patients with chronic heart failure and a preserved ejection fraction: rationale for and design of the EMPEROR Preserved Trial. Eur. J. Heart Fail. 21, 1279–1287 (2019).

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Renal Research Laboratory, Kolling Institute, University of Sydney, Royal North Shore Hospital, St. Leonards, Sydney, Australia

    Usha Panchapakesan & Carol Pollock

Authors
  1. Usha Panchapakesan
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Carol Pollock
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Carol Pollock.

Ethics declarations

Competing interests

C.P. is an Advisory Board member for Astra Zeneca and Boehringer Ingelheim, and a member of the Steering Committee of CREDENCE. U.P. declares no competing interests.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Panchapakesan, U., Pollock, C. Organ protection beyond glycaemic control with SGLT2 inhibitors. Nat Rev Nephrol 17, 223–224 (2021). https://doi.org/10.1038/s41581-020-00373-4

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/s41581-020-00373-4

  • Springer Nature Limited

This article is cited by

Search

Navigation